Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio

Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved

Idorsia announces financial results for the first quarter 2019

Idorsia issues invitation to 2019 Annual General Meeting of Shareholders

Idorsia announces financial results for 2018 - outstanding progress made - four late stage assets advanced into Phase 3

Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan

Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus

Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective

Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone

Idorsia maintains collaboration agreement with ReveraGen

Company statement

Idorsia financial results for the first nine months of 2018

Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer

Idorsia announces financial results for the first half 2018

Idorsia successfully completes the offering of new shares and the offering of convertible bonds thereby securing long-term funding for the development of its advancing pipeline

Idorsia launches the offering of new shares in combination with the offering of convertible bonds to fund the development of its advancing pipeline

Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management

Idorsia is initiating REACT - Phase 3 registration study with clazosentan

Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia

Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease